Synonyms: compound A [WO2022027058A1]
Compound class:
Synthetic organic
Comment: This compound in an IRAK4 degrader (PROTAC) that is claimed in Kymera Therapeutics' patent WO2022027058A1 [1]. It is intended as a therapeutic for B-cell lymphomas that express oncogenic mutations in MYD88, e.g. the protein variant MYD88L265P. The cereblon binding portion of the molecule is based on the structure of the immunomodulatory imide drug (IMiD) lenalidomide. Compound A simultaneously promotes the degradation of IRAK4 and the zinc-finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), and this mechanism synergistically targets key pro-survival pathways in B-cell lymphomas (MYD88-NFκB and IRF4-Type 1 interferon) to enhance anti-tumour activity. The chemical structure for Compound A matches that for the INN zomiradomide in proposed INN list 130 (Feb. 2024), and we suspect that this is their pipeline lead candidate KT-413.
We have curated structural and other information for a different clinical stage Kymera IRAK4/IMDi PROTAC known as KT-474 that is being evaluated for efficacy in autoinflammatory diseases. |
|
Classification | |
Compound class | Synthetic organic |
Ligand families/groups | PROTACs, molecular glues and other degraders |
International Nonproprietary Names | |
INN number | INN |
12914 | zomiradomide |
Synonyms |
compound A [WO2022027058A1] |
Database Links | |
CAS Registry No. | 2655656-99-6 (source: WHO INN record) |
GtoPdb PubChem SID | 461663459 |
PubChem CID | 156506667 |
Search Google for chemical match using the InChIKey | WDRJGMSUTPVXDH-KBOGUJPVSA-N |
Search Google for chemicals with the same backbone | WDRJGMSUTPVXDH |
Search PubMed clinical trials | zomiradomide |
Search PubMed titles | zomiradomide |
Search PubMed titles/abstracts | zomiradomide |
UniChem Compound Search for chemical match using the InChIKey | WDRJGMSUTPVXDH-KBOGUJPVSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | WDRJGMSUTPVXDH-KBOGUJPVSA-N |